白血病患者化疗后应用白介素-2治疗的临床观察

目的：探讨白血病患者化疗后应用白介素-2（IL-2）治疗的临床疗效.方法：将50例白血病患者随机分治疗组和对照组,治疗组化疗后加入IL-2 100万U/d×14 d,对照组单用化疗,监测两组治疗前、后T淋巴细胞亚群及化疗后患者的临床疗效、不良反应.结果：治疗组治疗2周后T淋巴细胞亚群水平明显高于治疗前及对照组化疗后（P＜0.05）.治疗组完全缓解（CR）率与总有效（OR）率与对照组相近,但粒细胞缺乏发生率、持续时间及感染发生率低于对照组（P＜0.05）.结论：应用IL-2对化疗后患者进行治疗可明显提高T淋巴细胞亚群水平,并可减少化疗后不良反应.

Clinical observation of the effect of interleukin-2 on leukemia patients after chemotherapy

Objective： To investigate the clinical effect of interleukin-2 （IL-2） on leukemia patients after chemotherapy. Methods： 50 leukemia patients were randomized into the treatment group and the control group. The treatment group received 1,000,000 units of IL-2 daily for 14 days immedi ately after chemotherapy, while the control group received no IL-2 after chemotherapy. The level changes of T lymphocyte subgroup, the clinical effect and the adverse reactions of the patients before and after the treatment with IL-2 were monitored. Results： After 14 days＇ treatment, the level of T lymphocyte subgroup in the treatment group was significantly higher than those before the treatment and those in the control group after chemotherapy （P〈0.05）. The complete remission （CR） rate and overall response （OR） rate in the treatment group was similar to those in the control group, but the incidence rate of agranulocytosis, duration and the incidence rate of infection in the treatment group was significantly lower than those in the control group （P〈0.05）. Conclusion： The application of IL-2 to treating leukemia patients after chemotherapy can obviously increase the level of T lymphocyte subgroup and release the adverse effects caused by chemotherapy.